ArticleAmerican journal of cancer research2017
Flot2 promotes tumor growth and metastasis through modulating cell cycle and inducing epithelial-mesenchymal transition of hepatocellular carcinoma.
Article in American journal of cancer research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 33 citations in OpenAlex.
- HNRNPH1 stabilizes FLOT2 mRNA in a non-canonical m6A-dependent manner to promote malignant progression in nasopharyngeal carcinoma.Cellular oncology (Dordrecht, Netherlands) · 2024Article
- Integrated analysis identities Rho GTPases related molecular map in patients with gastric carcinoma.Scientific reports · 2023Article
- Dawn-to-dusk dry fasting induces anti-atherosclerotic, anti-inflammatory, and anti-tumorigenic proteome in peripheral blood mononuclear cells in subjects with metabolic syndrome.Metabolism open · 2022Article
- Neural stem cell‑derived exosomes transfer miR‑124‑3p into cells to inhibit glioma growth by targeting FLOT2.International journal of oncology · 2022Article
- FLOT2 Promotes the Proliferation and Epithelial-mesenchymal Transition of Cervical Cancer by Activating the MEK/ERK1/2 Pathway.Balkan medical journal · 2022Article
- The differential role of the lipid raft-associated protein flotillin 2 for progression of myeloid leukemia.Blood advances · 2022Article
- SPC25 promotes hepatocellular carcinoma metastasis via activating the FAK/PI3K/AKT signaling pathway through ITGB4.Oncology reports · 2022Article
- TBL1X and Flot2 form a positive feedback loop to promote metastasis in nasopharyngeal carcinoma.International journal of biological sciences · 2022Article
- The Potential Role of Exosomal Proteins in Prostate Cancer.Frontiers in oncology · 2022Review
- PCSK9 promotes tumor growth by inhibiting tumor cell apoptosis in hepatocellular carcinoma.Experimental hematology & oncology · 2021Article
- Distinct DNA methylation patterns associated with treatment resistance in metastatic castration resistant prostate cancer.Scientific reports · 2021Article
- Article
- Effect of long non‑coding RNA AK021443 on promoting hepatic fibrosisMolecular medicine reports · 2021Article
- miR-34a-5p functions as a tumor suppressor in head and neck squamous cell cancer progression by targeting Flotillin-2.International journal of biological sciences · 2021Article
- SLC1A4: A Powerful Prognostic Marker and Promising Therapeutic Target for HCC.Frontiers in oncology · 2021Article
- Flotillin membrane domains in cancer.Cancer metastasis reviews · 2020Review
- NT5DC2 promotes tumor cell proliferation by stabilizing EGFR in hepatocellular carcinoma.Cell death & disease · 2020Article
- Flotillin-2 predicts poor prognosis and promotes tumor invasion in intrahepatic cholangiocarcinoma.Oncology letters · 2020Article
- Copy number variations ofTranslational cancer research · 2020Article
- Insufficient radiofrequency ablation promotes the metastasis of residual hepatocellular carcinoma cells via upregulating flotillin proteins.Journal of cancer research and clinical oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Flotillin-2 (Flot2) is a highly conserved and ubiquitously expressed protein that resides on the cytoplasmic side of the cell membrane within specific cholesterol rich microdomains. Some studies have reported that overexpression of Flot2 is related to cancer progression. However, the role of Flot2 in hepatocellular carcinoma (HCC) remains unclarified. In this study, we aim to explore the correlation between Flot2 expression and HCC progression and the underlying mechanism. In the present study, overexpression of Flot2 in HCC tissues and cell lines was detected, and forced overexpression of Flot2 significantly promoted the proliferation, migration, invasion and metastasis of HCC in vitro and in vivo by modulating cell cycle and inducing EMT, which was mediated via up-regulation of Twist as a result of Raf/MEK/ERK1/2 pathway activation. In contrast, silencing Flot2 expression inhibited these biological processes. Furthermore, high expression of Flot2 was significantly correlated with poor prognosis of HCC patients after curative resection and is an independent risk factor. In conclusion, Flot2 promoted tumor growth and metastasis of HCC through modulating cell cycle and inducing EMT. The expression of Flot2 may play a key role in HCC progression and may be regarded as a potential poor prognostic marker for HCC.
Indexed as
Identifiers
28560058PMC5446475W2987031765What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.